CoChat

Ketamine for depression: evidence, challenges and promise

Open access
Zarate, Carlos A., Niciu, Mark J. · 2015 · World Psychiatry
Cited by 61

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Major depressive disorder and bipolar depression are among the most prevalent and disabling mental disorders worldwide. Real-world effectiveness trials in major depressive disorder have underscored that most pharmacological options target monoamines, which are involved in a minority (15-20%) of synaptic contacts in the mammalian brain. Most synapses (∼50%) use the amino acid glutamate as their primary neurotransmitter, and preclinical models of depression have implicated aberrant glutamatergic neurotransmission for 25 years 1. More recently, the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine was shown to produce rapid and robust antidepressant effects in patients with treatment-resistant major depressive disorder and bipolar depression 2-7. Ketamine is a non-competitive NMDA receptor antagonist that works as an open channel pore blocker at the phencyclidine binding site, thereby preventing the flux of cations (primarily calcium) and neuronal excitation/depolarization. Several randomized, placebo-controlled trials of sub-anesthetic dose ketamine infusions (0.5 mg/kg for 40 min) have been conducted in individuals with major depressive disorder, including those with treatment-resistant depression 2-4. Sub-anesthetic dose ketamine also has similar antidepressant efficacy in treatment-resistant bipolar depression subjects maintained on mood stabilizers 5, and has not demonstrated increased affective switching to hypo/mania over placebo 8. Ketamine has also been shown to rapidly reduce suicidal thinking 6, 7. Because few evidence-based treatments for suicidality exist – none of which have rapid onset – ketamine may be a promising rapid-acting antidepressant treatment option in emergency and acute inpatient psychiatry. Finally, repeated sub-anesthetic dose ketamine infusions have demonstrated preliminary efficacy and safety/tolerability in brief trials 9. All the aforementioned placebo-controlled trials have used racemic ketamine mixtures. The S-enantiomer (S-ketamine/esketamine) has three- to four-fold greater affinity for the NMDA receptor, which may permit lower dosing to preserve antidepressant efficacy while limiting undesirable side effects. Non-intravenous modes of ketamine administration have also been studied (intramuscular, subcutaneous, oral, sublingual and intranasal), with mixed efficacy but typically fewer side effects than intravenous infusion. Specific ketamine metabolites have also been shown to correlate with antidepressant response 10; some have affinity for non-NMDA receptors (e.g., antagonism of alpha 7 nicotinic acetylcholine receptors) 11, which may also contribute to their antidepressant mechanism of action. In that regard, ketamine's antidepressant mechanism has been an active topic of preclinical and clinical investigation. Ketamine-induced NMDA receptor antagonism of inhibitory gamma-aminobutyric acid (GABA)ergic cortical interneurons has been shown to release tonic inhibition of excitatory (glutamatergic) pyramidal neurons to increase synaptic glutamate release (acute "glutamate surge") 12. Because postsynaptic NMDA receptors are blocked, synaptic glutamate can then preferentially bind to and activate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors 13. Postsynaptic membrane depolarization then initiates intracellular second messenger/signal transduction cascades, resulting in some or all of the following: mammalian target of rapamycin (mTOR) activation 14, increased brain-derived neurotrophic factor (BDNF) translation and secretion 15, and glycogen synthase kinase-3 (GSK-3) inhibition 16. These acute molecular and cellular responses to ketamine stimulate synaptic plasticity. Clinical neurobiological studies have focused on more amenable units of analysis, namely genetics, peripheral measures, and neuroimaging (including sleep electroencephalography). Some of them may be critical mediators of antidepressant response to ketamine, including BDNF genotype, circulating BDNF levels, acute changes in central glutamate levels, synaptic potentiation, and circuit-level de/synchronization 17. Although a handful of psychiatrists and anesthesiologists are currently administering ketamine in office-based outpatient settings, significant challenges exist for ketamine's potential broader dissemination in treating major depression. First, ketamine is not approved by the U.S. Food and Drug Administration (FDA) for any depressive disorder; this lack of indication may hamper dissemination, with concomitant public health implications. Yet, for ketamine to be more widely disseminated clinically, standardization of best practices must be put in place for optimal mode of administration, dosing and frequency. Several studies are currently investigating alternative modes of administration (e.g., intranasal esketamine), but none are comparing different modes head-to-head. For optimal dosing, with the exception of a small (N=4), placebo-controlled, crossover study 18,

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/wps.20269

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 61

Metadata

Authors
Zarate, C. A., & Niciu, M. J.
Venue
World Psychiatry
Publisher
Wiley
Published
2015-09-25
Volume
14
Issue
3
Pages
348-350
ISSN
  • 1723-8617 (ISSN-L)
  • 2051-5545
OpenAlex
W2121208444
Cited by
61
References
14
FWCI
4.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.